RxDoctor Payments Data

Andrea Warburton, PA

Physician Assistant · Henderson, NVNPI 1588022560

Payments from drug & device makers

$2,924in general payments, 2019–2025

Across 121 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$814
  • AstraZeneca$504
  • AbbVie$290
  • Amgen$244
  • Novo Nordisk$210
  • Astellas Pharma US Inc$172
  • plus $690 from 23 others

What the payments were for

  • Consulting fees$80027%
  • Food & beverage$2,02869%
  • Education$973%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,924 in reported general payments places this provider in the 80th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$96,040
Medicare patients
204
Services billed
1,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$127,882
MounjaroTirzepatide24$25,358
EliquisApixaban30$19,629
FarxigaDapagliflozin Propanediol31$19,233
TrulicityDulaglutide11$19,151
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$17,311
SymproicNaldemedine Tosylate11$5,005
PremarinEstrogens, Conjugated12$2,650
Oxycodone Hcl61$1,898
Rosuvastatin Calcium78$1,714
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl17$1,706
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen61$1,678
Alprazolam111$1,528
ProgesteroneProgesterone, Micronized38$1,314
Ezetimibe21$1,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$210$127,882126 claims
Lilly USA, LLCMounjaro, Trulicity$23$44,50935 claims
AstraZenecaFarxiga, Breztri Aerosphere$504$36,54444 claims
PfizerEliquis, Premarin$48$22,27942 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →